Navigation Links
Savara Expands Board of Directors, Appoints Three New Members

Nevan Elam, Former Head of Nektar Therapeutic's Pulmonary Business Unit, Among New Board of Directors Members

AUSTIN, Texas, March 4 /PRNewswire/ -- Savara, Inc., a biopharmaceutical company developing novel respiratory therapeutics utilizing its NanoCluster dry-powder formulation technology, today announced that it has expanded its Board of Directors and elected three new members.

Nevan Elam, former head of the pulmonary business unit at Nektar Therapeutics, has been appointed to fill a seat previously held by Cory Berkland, Ph.D. The board has also been expanded from three members to five, with Curt Bilby, Ph.D., and Matthew Dennis filling the new seats.

"We are honored to have these new members join the Board of Directors," said Rob Neville, Executive Chairman of the Board of Savara. "Their experience, including Mr. Elam's proven track record in the pulmonary drug delivery space, will provide an essential perspective as we respond to increasing interest in our platform NanoCluster technology."

"Savara's formulation technology combines the features of nanoparticles in structured microparticles to yield a powder with ideal aerodynamic properties for inhalation. Their approach is unique and addresses many of the challenges associated with existing formulation technologies. I am excited to be a part this company and to help guide the next generation pulmonary drug delivery technology," said Mr. Elam.

Mr. Elam, 41, is a former member of the executive management team of Nektar Therapeutics where he served as senior vice president, head of the pulmonary business unit. In this role, he oversaw all pulmonary business including research and development, manufacturing and strategic partnerships. Most recently Mr. Elam was responsible for the sale of Nektar's pulmonary business to Novartis for $115 million on Dec. 31, 2008.

Dr. Bilby, 49, is president & CEO of Terapio, a pharmaceutical company developing a pipeline of protein-based therapeutics. He is a four-time biotechnology CEO with more than 20 years of entrepreneurial leadership and executive management experience - both domestically and in Europe. Dr. Bilby also serves as Chairman of BioAustin.

Mr. Dennis, 41, is currently senior director of International Equities, Invesco AIM. As a global equity strategist, he has extensive experience analyzing business models, corporate strategies and market trends with a particular emphasis on the European pharmaceutical industry. He is involved in several different funds and mandates with a collective net asset value of approximately $11 billion, and is directly responsible for managing $6 billion of international and global equity assets.

About Savara, Inc.

Savara ( is developing next generation pulmonary drug delivery solutions using its NanoCluster formulation technology, which is now available for evaluation and license. Medicines manufactured using the NanoCluster technology are formulated directly from nanoparticle actives without the need for carrier particles or spray drying. The aerodynamics of NanoCluster formulations are fully customizable and permit targeted deposition of medicines to specific lung regions, including the deep lung. Savara expects that these NanoCluster features will translate into numerous patient benefits including reduced doses, enhanced efficacy, improved safety and tolerability as well as greater patient convenience.

    Contact Information

    Ian Stone
    Russo Partners, LLC
    (619) 528-2220

    Josef Bossart
    (512) 535-3613

    Rob Neville
    (512) 970-4740

SOURCE Savara, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Medical Affairs Company Expands Its Medical Communications Division
2. Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia
3. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
4. CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer
5. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
6. Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Yourway Transport Expands Biological Services
9. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
10. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
11. Yourway Transport Expands
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):